<p><em>PureTech 將繼續在倫敦證券交易所保持其主要上市</em></p>
<p><em>預計簡化上市結構將提升運營效率，並將資源集中於推進公司的投資組合</em></p>
<p>波士頓 --（商業資訊）--PureTech Health plc（納斯達克：PRTC，倫敦證券交易所：PRTC）（&#34;PureTech&#34;或&#34;公司&#34;），一家致力於將科學變為現實並將創新轉化為價值的中心輻射式生物治療公司，今天宣佈已通知納斯達克證券市場有限責任公司（“納斯達克”）其自願退市美國存托股票（“ADSs”）的意圖，每個 ADS 代表有權接收公司十（10）股普通股。在退市生效後，PureTech 的普通股將繼續在倫敦證券交易所（“LSE”）上市，該交易所將繼續作為公司的主要交易場所。</p>
<p>經過對公司上市結構和股東交易模式的審查，董事會決定維持雙重上市已不再必要。PureTech 股票的絕大多數交易量、流動性和價格發現發生在倫敦證券交易所，而公司當前投資者基礎的主要部分以及公司的治理框架均集中在英國。</p>
<p>這一決定反映了 PureTech 對嚴格資本配置、專注執行和長期股東價值創造的持續承諾。維持雙重上市的成本以及監管和行政要求是相當大的，集中交易於倫敦證券交易所將簡化治理、精簡開支，並使公司的結構與其運營和戰略優先事項保持一致。</p>
<p>在退市後，直到 PureTech 考慮終止其美國存託憑證（“ADR”）計劃為止，PureTech 預計其 ADS 將在場外市場通過贊助的一級 ADR 計劃進行報價和交易。此時，ADS 持有者無需採取任何行動。</p>
<p>PureTech 首席執行官 Robert Lyne 評論道：</p>
<p>“我們已確定，將我們的上市集中在倫敦證券交易所是支持我們的股東和執行我們戰略的最有效方式。這個決定反映了我們股票的有意義交易量和流動性始終發生的地方，同時保持對英國和全球投資社區的訪問。通過簡化我們的上市結構，我們正在精簡開支、保護資本，並確保我們的資源集中於推進我們差異化的投資組合並創造長期價值。”</p>
<p>PureTech 預計將在 2026 年 5 月 11 日左右向美國證券交易委員會（“SEC”）提交一份 25 號表格，涉及其 ADS 的退市。退市預計將在十天後生效，PureTech 的 ADS 在納斯達克的最後交易日預計在 2026 年 5 月 20 日左右。</p>
<p>在退市後，PureTech 打算向 SEC 提交一份 15F 表格，以註銷其證券並終止其根據 1934 年證券交易法（“交易法”）的報告義務。提交該表格後，公司的報告義務將立即暫停。如果 SEC 沒有異議，公司的註冊和報告義務的終止預計將在提交後不超過 90 天內生效。</p>
<p><strong>關於 PureTech Health</strong></p>
<p>PureTech Health 是一家中心輻射式生物治療公司，致力於將科學變為現實並將創新轉化為價值。我們通過一種經過驗證的、資本高效的研發模式來實現這一目標，專注於具有驗證藥理學和未開發潛力的機會，以滿足重要的患者需求。這一戰略已經產生了數十個治療候選藥物，其中三個已獲得美國 FDA 批准。通過識別、塑造和降低這些高信念資產的風險，並通過外部資本支持的專門結構進行規模化，我們加速了它們通往患者的路徑，同時為股東創造可持續價值。</p>
<p>欲瞭解更多信息，請訪問 www.puretechhealth.com 或在 LinkedIn 和 X（前身為 Twitter）上與我們聯繫 @puretechh。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本新聞稿包含的聲明可能是 1995 年《私人證券訴訟改革法》意義上的前瞻性聲明。本新聞稿中所有與歷史事實無關的聲明應視為前瞻性聲明，包括但不限於與我們在美國的退市和註銷及相關時間、ADS 未來交易、未來前景、發展和戰略相關的聲明。前瞻性聲明基於當前預期，並受到已知和未知的風險、不確定性及其他重要因素的影響，這些因素可能導致實際結果、表現和成就與當前預期有重大差異，包括但不限於在我們向 SEC 提交的 2025 年 12 月 31 日結束的 20-F 表格年度報告及其他監管文件中描述的 “風險因素” 下的風險、不確定性及其他重要因素。這些前瞻性聲明基於關於公司當前和未來商業戰略及其未來運營環境的假設。每個前瞻性聲明僅在本新聞稿發佈之日有效。除法律和監管要求外，我們不承擔更新或修訂這些前瞻性聲明的任何義務，無論是由於新信息、未來事件還是其他原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg1MzkwNjFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg1MzkwNjFyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260428539061/en/</p>
<p><strong>PureTech</strong></p>
<p>公共關係</p>
<p>publicrelations@puretechhealth.com</p>
<p>投資者關係</p>
<p>IR@puretechhealth.com</p>
<p><strong>英國/歐盟媒體</strong></p>
<p>Ben Atwell, Rob Winder</p>
<p>+44 (0) 20 3727 1000</p>
<p>puretech@fticonsulting.com</p>
<p><strong>美國媒體</strong></p>
<p>Justin Chen</p>
<p>jchen@tenbridgecommunications.com</p>
<p>來源：PureTech Health plc</p>

PRTC

PRTCY

<p>PureTech Health plc 宣佈其計劃自願將其美國存托股票（ADSs）從納斯達克退市，專注於在倫敦證券交易所（LSE）進行交易。此決定旨在提高運營效率，並與公司在英國的主要投資者基礎保持一致。退市預計將在 2026 年 5 月 20 日左右生效，屆時將向美國證券交易委員會（SEC）提交 Form 25。PureTech 的首席執行官強調，此舉將簡化治理結構並保護資本，使公司能夠專注於推進其生物治療產品組合</p>

<p><em>PureTech to maintain its primary listing on the London Stock Exchange</em></p>
<div class="lb-trans"><p><em>PureTech 將繼續在倫敦證券交易所保持其主要上市</em></p>
</div><p><em>Simplification of listing structure expected to enhance operational efficiency and focus resources on advancing the Company’s portfolio</em></p>
<div class="lb-trans"><p><em>預計簡化上市結構將提升運營效率，並將資源集中於推進公司的投資組合</em></p>
</div><p>BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (&#34;PureTech&#34; or the &#34;Company&#34;), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has notified The Nasdaq Stock Market LLC (“Nasdaq”) of its intention to voluntarily delist its American Depositary Shares (“ADSs”), each representing the right to receive ten (10) ordinary shares of the Company. Following the effectiveness of the delisting, PureTech’s ordinary shares will remain listed on the London Stock Exchange (“LSE”), which will continue to serve as the Company’s primary trading venue.</p>
<div class="lb-trans"><p>波士頓 --（商業資訊）--PureTech Health plc（納斯達克：PRTC，倫敦證券交易所：PRTC）（&#34;PureTech&#34;或&#34;公司&#34;），一家致力於將科學變為現實並將創新轉化為價值的中心輻射式生物治療公司，今天宣佈已通知納斯達克證券市場有限責任公司（“納斯達克”）其自願退市美國存托股票（“ADSs”）的意圖，每個 ADS 代表有權接收公司十（10）股普通股。在退市生效後，PureTech 的普通股將繼續在倫敦證券交易所（“LSE”）上市，該交易所將繼續作為公司的主要交易場所。</p>
</div><p>Following a review of the Company’s listing structure and shareholder trading patterns, the Board of Directors determined that maintaining a dual listing is no longer necessary. The substantial majority of trading volume, liquidity, and price discovery for PureTech’s shares occurs on the LSE, and the majority of the Company’s current investor base as well as the Company’s governance framework are centered in the United Kingdom.</p>
<div class="lb-trans"><p>經過對公司上市結構和股東交易模式的審查，董事會決定維持雙重上市已不再必要。PureTech 股票的絕大多數交易量、流動性和價格發現發生在倫敦證券交易所，而公司當前投資者基礎的主要部分以及公司的治理框架均集中在英國。</p>
</div><p>This decision reflects PureTech’s ongoing commitment to disciplined capital allocation, focused execution, and long-term shareholder value creation. The cost and regulatory and administrative demands of maintaining a dual listing are significant, and concentrating trading on the London Stock Exchange will simplify governance, streamline overhead, and align the Company’s structure with its operational and strategic priorities.</p>
<div class="lb-trans"><p>這一決定反映了 PureTech 對嚴格資本配置、專注執行和長期股東價值創造的持續承諾。維持雙重上市的成本以及監管和行政要求是相當大的，集中交易於倫敦證券交易所將簡化治理、精簡開支，並使公司的結構與其運營和戰略優先事項保持一致。</p>
</div><p>Following the delisting, and until such time as PureTech may consider terminating its American Depositary Receipt (“ADR”) program, PureTech expects its ADSs to be quoted and traded on the over-the-counter market via a sponsored Level 1 ADR program. No action is required to be taken by ADS holders at this time.</p>
<div class="lb-trans"><p>在退市後，直到 PureTech 考慮終止其美國存託憑證（“ADR”）計劃為止，PureTech 預計其 ADS 將在場外市場通過贊助的一級 ADR 計劃進行報價和交易。此時，ADS 持有者無需採取任何行動。</p>
</div><p>Robert Lyne, Chief Executive Officer of PureTech, commented:</p>
<div class="lb-trans"><p>PureTech 首席執行官 Robert Lyne 評論道：</p>
</div><p>“We have determined that concentrating our listing on the London Stock Exchange is the most effective way to support our shareholders and execute our strategy. This decision reflects where the meaningful trading volume and liquidity in our shares has consistently occurred, whilst maintaining access to both the UK and global investment community. By simplifying our listing structure, we are streamlining overhead, preserving capital, and ensuring that our resources are focused on advancing our differentiated portfolio and delivering long-term value.”</p>
<div class="lb-trans"><p>“我們已確定，將我們的上市集中在倫敦證券交易所是支持我們的股東和執行我們戰略的最有效方式。這個決定反映了我們股票的有意義交易量和流動性始終發生的地方，同時保持對英國和全球投資社區的訪問。通過簡化我們的上市結構，我們正在精簡開支、保護資本，並確保我們的資源集中於推進我們差異化的投資組合並創造長期價值。”</p>
</div><p>PureTech expects to file a Form 25 with the U.S. Securities and Exchange Commission (“SEC”) relating to the delisting of its ADSs on or about May 11, 2026. The delisting is expected to become effective ten days thereafter, with the last day of trading of the Company’s ADSs on Nasdaq expected to be on or about May 20, 2026.</p>
<div class="lb-trans"><p>PureTech 預計將在 2026 年 5 月 11 日左右向美國證券交易委員會（“SEC”）提交一份 25 號表格，涉及其 ADS 的退市。退市預計將在十天後生效，PureTech 的 ADS 在納斯達克的最後交易日預計在 2026 年 5 月 20 日左右。</p>
</div><p>Following the delisting, PureTech intends to file a Form 15F with the SEC to deregister its securities and terminate its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Upon such filing, the Company’s reporting obligations with the SEC will be suspended immediately. The termination of the Company’s registration and reporting obligations is expected to become effective no later than 90 days after such filing if there are no objections from the SEC.</p>
<div class="lb-trans"><p>在退市後，PureTech 打算向 SEC 提交一份 15F 表格，以註銷其證券並終止其根據 1934 年證券交易法（“交易法”）的報告義務。提交該表格後，公司的報告義務將立即暫停。如果 SEC 沒有異議，公司的註冊和報告義務的終止預計將在提交後不超過 90 天內生效。</p>
</div><p><strong>About PureTech Health</strong></p>
<div class="lb-trans"><p><strong>關於 PureTech Health</strong></p>
</div><p>PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&amp;D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.</p>
<div class="lb-trans"><p>PureTech Health 是一家中心輻射式生物治療公司，致力於將科學變為現實並將創新轉化為價值。我們通過一種經過驗證的、資本高效的研發模式來實現這一目標，專注於具有驗證藥理學和未開發潛力的機會，以滿足重要的患者需求。這一戰略已經產生了數十個治療候選藥物，其中三個已獲得美國 FDA 批准。通過識別、塑造和降低這些高信念資產的風險，並通過外部資本支持的專門結構進行規模化，我們加速了它們通往患者的路徑，同時為股東創造可持續價值。</p>
</div><p>For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.puretechhealth.com 或在 LinkedIn 和 X（前身為 Twitter）上與我們聯繫 @puretechh。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our delisting and deregistration in the U.S. and related timing, plans for future trading of ADSs, future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption &#34;Risk Factors&#34; in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新聞稿包含的聲明可能是 1995 年《私人證券訴訟改革法》意義上的前瞻性聲明。本新聞稿中所有與歷史事實無關的聲明應視為前瞻性聲明，包括但不限於與我們在美國的退市和註銷及相關時間、ADS 未來交易、未來前景、發展和戰略相關的聲明。前瞻性聲明基於當前預期，並受到已知和未知的風險、不確定性及其他重要因素的影響，這些因素可能導致實際結果、表現和成就與當前預期有重大差異，包括但不限於在我們向 SEC 提交的 2025 年 12 月 31 日結束的 20-F 表格年度報告及其他監管文件中描述的 “風險因素” 下的風險、不確定性及其他重要因素。這些前瞻性聲明基於關於公司當前和未來商業戰略及其未來運營環境的假設。每個前瞻性聲明僅在本新聞稿發佈之日有效。除法律和監管要求外，我們不承擔更新或修訂這些前瞻性聲明的任何義務，無論是由於新信息、未來事件還是其他原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA0Mjg1MzkwNjFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260428539061r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260428539061/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260428539061/en/</p>
</div><p><strong>PureTech</strong></p>
<div class="lb-trans"><p><strong>PureTech</strong></p>
</div><p>Public Relations</p>
<div class="lb-trans"><p>公共關係</p>
</div><p>publicrelations@puretechhealth.com</p>
<div class="lb-trans"><p>publicrelations@puretechhealth.com</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>IR@puretechhealth.com</p>
<div class="lb-trans"><p>IR@puretechhealth.com</p>
</div><p><strong>UK/EU Media</strong></p>
<div class="lb-trans"><p><strong>英國/歐盟媒體</strong></p>
</div><p>Ben Atwell, Rob Winder</p>
<div class="lb-trans"><p>Ben Atwell, Rob Winder</p>
</div><p>+44 (0) 20 3727 1000</p>
<div class="lb-trans"><p>+44 (0) 20 3727 1000</p>
</div><p>puretech@fticonsulting.com</p>
<div class="lb-trans"><p>puretech@fticonsulting.com</p>
</div><p><strong>US Media</strong></p>
<div class="lb-trans"><p><strong>美國媒體</strong></p>
</div><p>Justin Chen</p>
<div class="lb-trans"><p>Justin Chen</p>
</div><p>jchen@tenbridgecommunications.com</p>
<div class="lb-trans"><p>jchen@tenbridgecommunications.com</p>
</div><p>Source: PureTech Health plc</p>
<div class="lb-trans"><p>來源：PureTech Health plc</p>
</div>

PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange | PRTC Stock News

PureTech 宣佈計劃自願從納斯達克退市其美國存托股票，並將交易集中在倫敦證券交易所 | PRTC 股票新聞